Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$66.16
pos +0.00
+0.00%
Today's Range: 65.63 - 66.16 | MRK Avg Daily Volume: 10,996,800
Last Update: 02/24/17 - 4:01 PM EST
Volume: 0
YTD Performance: 11.86%
Open: $0.00
Previous Close: $65.85
52 Week Range: $50.09 - $66.16
Oustanding Shares: 2,757,137,517
Market Cap: 181,557,505,494
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 8 8
Moderate Buy 1 1 0 0
Hold 3 3 6 6
Moderate Sell 1 1 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.68 1.68 1.86 1.86
Latest Dividend: 0.47
Latest Dividend Yield: 2.86%
Dividend Ex-Date: 12/13/16
Price Earnings Ratio: 33.60
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
33.60 188.10 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.83% 30.91% 17.53%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.80 -0.38
Net Income -78.00 -0.80 -0.40
EPS -77.60 -0.80 -0.38
Earnings for MRK:
EBITDA 1.95B
Revenue 10.22B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.82 $0.85 $3.82 $4.16
Number of Analysts 5 5 8 8
High Estimate $0.89 $0.92 $3.88 $4.73
Low Estimate $0.73 $0.81 $3.77 $3.85
Prior Year $0.89 $0.93 $3.78 $3.82
Growth Rate (Year over Year) -7.64% -8.17% 1.03% 8.87%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
You have to keep up with the sector rotations.
These may be uncharted waters, but they're not necessarily expensive.
Icahn may have a tough time finding interest in this behemoth.
You might want to review your holdings in the sector.
Bearish
Feb 15, 2017 | 6:59 AM EST
Shares of MRK now seen reaching $70, according to BMO Capital. Epoch trial had disappointing results. Outperform rating.
Static doesn't work in this industry. Pipelines work.
Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie Real Money Pro($)

Getting FDA to streamline its approval process would boost drug makers.
M&A, drug approvals and Trump are all on my watch list.

Columnist Conversations

One of the fundamental concepts of market characteristics is they generally don't go straight up or straight d...
With less than an hour left in the session COP is trading below its January low. This key support area($47.20)...
tremendous flow here today and a big reversal candle. BOUGHT LB MAY 50 CALL AT 3.80 Poor reaction pos...
We have a nice gainer here, let's unload it SOLD OLED MAR 75 CALL AT 6.40 (in at 2.70)

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.